Document:

EX-10.10

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], 

HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT 

THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

Exhibit 10.10 
 AMENDMENT
NO. 1 
 TO THE LICENSE AGREEMENT 

BETWEEN LUPA BIO, INC. AND 
 THE
REGENTS OF THE UNIVERSITY OF CALIFORNIA 
 This Amendment No. 1 to the License Agreement (this “Amendment No. 1”) is entered into by and
between Lupa Bio, Inc. (hereinafter “LICENSEE”) and the Regents of the University of California (“UNIVERSITY”) represented by its San Diego campus (“UC San Diego”), each referred to herein as a “Party”, or
collectively as the “Parties”. Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the License Agreement. 

WHEREAS, and the University entered into a License Agreement, UC San Diego Control Number 2019003-0146 (the “Agreement”) effective
October 10, 2018 (“Effective Date”) whereby LICENSEE obtained certain rights from University for Therapeutic Products. 
 WHEREAS, the
Parties now wish to amend the Agreement, to be effective upon the date of last signature of this Amendment No. 1 (“Amendment No. 1 Effective Date”), to modify certain terms in the Agreement. 

NOW, THEREFORE, the Parties hereto agree as follows: 

With respect to the Preamble 
 The address of
LICENSEE shall be changed to: [***]. 
 Article 3. CONSIDERATION (d) shall be deleted and replaced with: 

(d) an earned royalty of [***] percent ([***]) on Net Sales of Licensed Products [***]; and [***] percent ([***]%) royalty on sales of Licensed Products that
utilize Technology, but not Patent Rights by LICENSEE, Sublicensees, and/or Affiliates; 
 Article 4.1. Reports (b), last paragraph shall be deleted
and replaced with: 
 If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting
period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number: “License Agreement between UC SAN DIEGO and Lupa Bio, Inc. for case number SD2018-048.” Reports shall be submitted as an attachment to UC SAN DIEGO’s email address: oic-reports@ucsd.edu. 

Article 10. MISCELLANEOUS PROVISIONS (c) 

Licensee’s address shall be changes as follows: 

 If sent to LICENSEE: 

Lupa Bio, Inc. 
 [***] 

[***] 
 Attention: [***] 

Phone: [***] 
 Email: [***] 

Exhibit D-Due Diligence shall be deleted and replaced with: 

 

					
	 Milestone
	  	 Due Date
	  	 Status

			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]

 Capitalized terms shall have the meaning assigned to them in the License Agreement. Except as expressly and
unambiguously stated herein, no other changes are made to the License Agreement. All other terms and conditions of the License Agreement shall remain in full force and effect. The License Agreement and this Amendment No.1constitute the entire
understanding of the parties with respect to the subject matter hereof and supersede any prior understanding, oral or written, between the parties with respect thereto. The License Agreement and Amendment No.1 shall be governed in all respects by
the laws of the State of California without regard to its conflict of laws provisions. 
 The parties agree that this Amendment No. 1 may be executed
electronically and in two (2) or more counterparts each of which shall be deemed an original and all of which together shall constitute but one and the same instrument. 

IN WITNESS WHEREOF, each of the parties has caused this Amendment No. 1 to the License to be executed by a duly authorized representative. 

 

							
	LUPA BIO, INC.:	  	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA:
				
	By:	 	 /s/ Alex Martinez
	  	By:	 	 /s/ David Gibbons

	Name: Alex Martinez	  	David Gibbons
	Title: CEO	  	Associate Director
				
	Date:	 	10/10/2019	  	Date:	 	10/10/2019EX-10.11

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], 

HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT 

THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

Exhibit 10.11 
 AMENDMENT
NO. 2 
 TO THE LICENSE AGREEMENT 

BETWEEN INTRINSIC MEDICINE, INC. (FKA LUPA BIO, INC.) AND 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 
 This
Amendment No. 2 to the License Agreement (this “Amendment No. 2”) is entered into by and between Intrinsic Medicine, Inc. (fka Lupa Bio, Inc.) (hereinafter “LICENSEE”) and the Regents of the University of California
(“UNIVERSITY”) represented by its San Diego campus (“UC San Diego”), each referred to herein as a “Party”, or collectively as the “Parties”. Capitalized terms used herein and not otherwise defined have the
meanings ascribed to them in the License Agreement. 
 WHEREAS, and the University entered into a License Agreement, UC San Diego Control Number 2019-03-0146 (the “Agreement”) effective October 10, 2018 (“Effective Date”) whereby LICENSEE obtained certain rights from University for Therapeutic
Products. 
 WHEREAS, the Parties amended the Agreement with Amendment No. 1, UC San Diego Control Number 2019-03-0146 (R501), effective October 10, 2019 to modify certain terms in the Agreement. 
 WHEREAS,
the Parties now wish to amend the Agreement, to be effective upon the date of last signature of this Amendment No. 2 (“Amendment No. 2 Effective Date”), to modify certain terms in the Agreement. 

NOW, THEREFORE, the Parties hereto agree as follows: 

Amendment Fee 
 Within thirty (30) days of the
Amendment No. 2 Effective Date, LICENSEE will pay to UNIVERSITY an amendment fee of three thousand dollars ($3,000). 
 With respect to the
Preamble 
 The address of LICENSEE shall be changed to: [***]. 

Article 4.1. Reports (b), last paragraph shall be deleted and replaced with: 

If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report.
The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number: “License Agreement between UC SAN DIEGO and Intrinsic Medicine, Inc. for case number
SD2018-048.” Reports shall be submitted as an attachment to UC SAN DIEGO’s email address: oic-reports@ucsd.edu. 

  
 1 

 Article 10. MISCELLANEOUS PROVISIONS (c) 

Licensee’s address shall be changes as follows: 
 If sent to
LICENSEE: 
 Intrinsic Medicine, Inc. 

[***] 
 [***] 

Attention: [***] 
 Phone: [***]

 Email: [***] 
 Exhibit C –
Milestone Payments shall be deleted and replaced with: 
  

			
	 Milestone
	  	 Payment

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 Exhibit D-Due Diligence shall be deleted and replaced with: 

 

					
	 Milestone
	  	 Due Date
	  	 Status

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]

  
 2 

 Capitalized terms shall have the meaning assigned to them in the License Agreement. Except as expressly and
unambiguously stated herein, no other changes are made to the License Agreement. All other terms and conditions of the License Agreement shall remain in full force and effect. The License Agreement, Amendment No.1 and this Amendment No. 2 shall
constitute the entire understanding of the parties with respect to the subject matter hereof and supersede any prior understanding, oral or written, between the parties with respect thereto. The License Agreement, Amendment No.1 and this Amendment
No. 2 shall be governed in all respects by the laws of the State of California without regard to its conflict of laws provisions. 
 The parties agree
that this Amendment No. 2 may be executed electronically and in two (2) or more counterparts each of which shall be deemed an original and all of which together shall constitute but one and the same instrument. 

[SIGNATURE PAGE FOLLOWS] 

  
 3 

 IN WITNESS WHEREOF, each of the parties has caused this Amendment No. 2 to the License to be executed
by a duly authorized representative. 
  

									
	INTRINSIC MEDICINE, INC.:	  	        	  	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA:
					
	By:	  	 /s/ Alexander Martinez
	  		  	By:	  	 Victoria Cajipe

	Name: Alexander Martinez	  		  	Victoria Cajipe, Ph.D.
	Title: CEO & Co-Founder	  		  	Associate Director
	Date:	  	11/30/2020	  		  	Date:	  	11/30/2020

  
 4 

 [***]EX-10.12

 Exhibit 10.12 

AMENDMENT NO. 3 
 TO THE LICENSE
AGREEMENT 
 BETWEEN INTRINSIC MEDICINE, INC. (FKA LUPA BIO, INC.) AND 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 
 This
Amendment No. 3 to the License Agreement (this “Amendment No. 3”) is entered into by and between Intrinsic Medicine, Inc. (fka Lupa Bio, Inc.) (hereinafter “LICENSEE”) and the Regents of the University of California
(“UNIVERSITY”) represented by its San Diego campus (“UC San Diego”), each referred to herein as a “Party”, or collectively as the “Parties”. Capitalized terms used herein and not otherwise defined have the
meanings ascribed to them in the License Agreement. 
 WHEREAS, LICENSEE and the University entered into a License Agreement, UC San Diego Control
Number 2019-03-0146 (as amended, the “Agreement”) effective October 10, 2018 (“Effective Date”) whereby LICENSEE obtained certain rights from
University for Therapeutic Products. 
 WHEREAS, the Parties amended the Agreement with Amendment No. 1, UC San Diego Control Number 2019-03-0146 (R501) effective October 10, 2019, and with Amendment No. 2, UC San Diego Control Number
2019-03-0146 (R502) effective November 30, 2020, to modify certain terms in the Agreement. 

WHEREAS, the Parties now wish to amend the Agreement, to be effective upon the date of last signature of this Amendment No. 3 (“Amendment
No. 3 Effective Date”), to modify certain terms in the Agreement. 
 NOW, THEREFORE, the Parties hereto agree as follows: 

Amendment Fee 
 Within thirty (30) days of the
Amendment No. 3 Effective Date, LICENSEE will pay to UNIVERSITY an amendment fee of twenty thousand dollars ($20,000). 
 With respect to the
Preamble 
 The address of LICENSEE shall be changed to: 

500 Yale Avenue North, Seattle, WA 98109 
 With respect to
Background 
 Paragraph A shall be deleted in its entirety and replace with the following: 

 

	A.	 The inventions disclosed in Exhibit A (“Inventions”) were made in the course of research at UC SAN
DIEGO by Dr. Lars Bode and his associates (hereinafter and collectively the “Inventors”), are related to the therapeutic application of 3”-sialyllactose (“3’SL” ) and 6’-sialyllactose (“6’SL”)
and are covered by Patent Rights as defined below. 

 With respect to Definitions 

Paragraph 1.15 shall be deleted in its entirety and replaced with the following: 

  
 1 

 1.15 “Therapeutic Products” means products that are Licensed Products that are considered drugs
pursuant to the definition of “drug” in 21 USC § 321(g)(1) or comprises a formulation, prodrug or derivative of 3’SL or 6’SL that would be considered a “drug” pursuant to the definition in 21 USC § 321(g)(1).

 Article 10. MISCELLANEOUS PROVISIONS 

Licensee’s address in 10 (c) shall be changed as follows: 

If sent to LICENSEE: 
 Intrinsic Medicine, Inc.

 500 Yale Avenue North 

Seattle, WA 98109. 
 Attention:
        Alex Martinez 

                        
  CEO and Chairman 
 Email: alex@intrinsicmedicine.com 

Cc to:     Dustin Crawford 

  General Counsel and VP, Corporate Development 

  dustin@intrinsicmedicine.co 

Exhibit D-Due Diligence 

Exhibit D shall be deleted in its entirety and replaced with the following: 
  

					
	 Milestone
	  	 Due Date
	  	 Status

	 [***]
	  	 [***]
	  	 [***]

			
	 [***]
	  	 [***]
	  	 [***]

			
	 [***]
	  	 [***]
	  	 [***]

			
	 [***]
	  	[***]	  	 [***]

			
	 [***]
  

[***]
	  	 [***]
  

[***] 
	  	
			
	[***]	  	 [***]
	  	
			
	[***]	  	 [***]
	  	

  
 2 

					
	 Milestone
	  	 Due Date
	  	 Status

	[***]	  	 [***]
	  	
			
	[***]	  	 [***]
	  	

 Capitalized terms shall have the meaning assigned to them in the Agreement. Except as expressly and unambiguously stated
herein, no other changes are made to the Agreement. All other terms and conditions of the Agreement shall remain in full force and effect. The Agreement, Amendment No. 1, Amendment No. 2 and this Amendment No. 3 shall constitute the
entire understanding of the parties with respect to the subject matter hereof and supersede any prior understanding, oral or written, between the parties with respect thereto. The Agreement, Amendment No. 1, Amendment No. 2 and this
Amendment No. 3 shall be governed in all respects by the laws of the State of California without regard to its conflict of laws provisions. 
 The
parties agree that this Amendment No. 3 may be executed electronically and in two (2) or more counterparts each of which shall be deemed an original and all of which together shall constitute but one and the same instrument. 

Signatures on page following 

  
 3 

 IN WITNESS WHEREOF, each of the parties has caused this Amendment No. 3 to the License to be executed
by a duly authorized representative. 
  

									
	INTRINSIC MEDICINE, INC.:	  		  	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA:
					
	By:	  	 /s/ Alexander Martinez
	  		  	By:	  	 /s/ Victoria Cajipe

	Name: Alexander Martinez	  		  	Victoria Cajipe
	Title: CEO & Co-Founder	  		  	Associate Director
	Date: 2/2/2022	  		  	Date: 2/2/2022

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]